Victoria Castel

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

Susan L. Cohn, Andrew D.J. Pearson, Wendy B. London et al. · Journal of Clinical Oncology · 2008 · 1.8K citations · Full text

Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.

Brodeur Gm, Jon Pritchard, Frank Berthold et al. · PubMed · 1994 · 392 citations

Neuro-oncology, International Criteria, Interdisciplinary Neurosurgery +7

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 379 citations

Interleukin 2, Autoimmune Disease, Anti-gd2 Antibody Ch14.18/cho +7

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

Wendy B. London, Victoria Castel, Tom Monclair et al. · Journal of Clinical Oncology · 2011 · 325 citations